The prevalence of depression among adolescent with HIV/AIDS: a systematic review and meta-analysis

Getinet Ayano1,2*, Sileshi Demelash3, Mebratu Abraha4 and Light Tsegay5

Abstract

Background: Depression is particularly common among adolescents with HIV/AIDS and has been associated with disruption of the important developmental process, subsequently leading to a wide range of negative mental, physical and psychosocial consequences, as well as poor quality of life in those population groups. Nevertheless, to the best of our knowledge, there are no prior systematic reviews and meta-analytic studies that determined the prevalence of depression among adolescents with HIV/AIDS.

Method: We systematically searched PubMed, Scopus and Web of Science for relevant literature until May 2020. A random-effect meta-analysis was used to pool prevalence rates from individual studies. Sensitivity and subgroup analyses were performed to identify the source of heterogeneities and to compare the prevalence estimates across the groups. The Joanna Briggs Institute’s quality assessment checklist was used to evaluate the quality of the included studies. Cochran’s Q and the I2 tests were used to assess heterogeneity between the studies.

Results: A total of ten studies were included for the final analysis, with 2642 adolescents living with HIV/AIDS. Our final meta-analysis showed that more than a quarter of adolescents with HIV had depression [26.07% (95% CI 18.92–34.78)]. The prevalence was highest amongst female adolescents (32.15%) than males (25.07%) as well as amongst the older adolescents aged 15–19 years (37.09%) than younger adolescents aged 10–14 years (29.82%).

Conclusion: Our study shows that a significant proportion of adolescents with HIV had depression, indicating the imperativeness of intervention strategies to alleviate the suffering and possibly reduce the probable negative ramifications.

Keywords: Depression, Adolescent, HIV, AIDS, Systematic review, Meta-analysis

In general, the reported prevalence of depression among adolescents with HIV/AIDS varies across the studies from 11.40 to 45.83% [3–10]. There are several factors, which are responsible for this significant difference in the prevalence of depression including (i) the variations in the characteristics of the adolescents across the studies regarding the severity of HIV infections, the stages of the disease, as well as the presence of opportunistic infections; (ii) the differences in the tools used to measure depression between the studies with various psychometric properties including sensitivity and specificity; (iii) the variation in clinical characteristics of participants.
including the presence of other mental health problems as well as additional psychosocial stress or trauma among the participants.

Epidemiological studies conducted in the past several decades show that the presence of depression among adolescents living with HIV/AIDS has been consistently associated with disruption of the important developmental process, subsequently leading to a wide range of negative mental, physical and psychosocial consequences, as well as poor physical health in those population groups [11, 12]. Complementing the above views, scientific studies revealed that the presence of depression among adolescents with HIV is linked with poor quality of life [12, 13], increased levels of stigma [13–15], poor social support [12], suicide [16], as well as a poor coping mechanism leading to a wide range of negative physical health problems and difficulties in managing social aspects of life [17]. Moreover, an emerging body of scientific evidence suggests that depression in early life has been linked with poor educational attainment, unemployment, as well as lower levels of perceived social sports (subjective judgments about the availability of help from friends and family during the times of need) [18–20]. Moreover, the presence of depression among adolescents living with HIV/AIDS is also linked with poor adherence to antiretroviral treatment (ART), which in turn associated with significant morbidity, mortality, increased resistance to ART drugs, severe disease, lower quality of life and short life expectancy due to untreated or inadequately treated problems [21–24]. Therefore, understanding the true magnitude of depression among adolescents with HIV is imperative for implementing possible early screening and suitable intervention strategies, subsequently reducing the suffering as well as the associated negative outcomes.

No systematic review and meta-analysis to date have estimated the consolidated prevalence of depression among adolescents living with HIV/AIDS. Evidence from such meta-analysis will provide robust information on the epidemiology of depression among adolescents with HIV/AIDS that would be necessary to plan early and suitable intervention strategies for those population groups. Therefore, the purpose of this review is to systematically analyze published studies on the prevalence of depression among adolescents with HIV/AIDS using both qualitative and quantitative methods.

**Research design and method**

This systematic review and meta-analysis was designed, conducted and reported in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [25]. The systematic searching, assessing eligibility, evaluating the quality, extracting data and analysis of data has been performed based on pre-designed protocol.

**Data source and selection process**

We searched PubMed, Scopus and Web of Science to identify relevant studies published in the English language until May 2020. The following keywords and terms were used to assess PubMed: [(depression or depressive symptom or mental health) and (adolescent or child or youth)] and (Human immunodeficiency virus or HIV or acquired immunodeficiency syndrome or AIDS). Scopus and Web of Science were searched using terms and words suitable for the databases. Additional relevant studies were collected by searching through the reference lists of eligible studies (Additional file 1: Fig. S1).

**Eligibility criteria and study selection**

Retrieved papers were included in this review if they satisfy the following criteria: (i) The study participants were adolescents with HIV/AIDS; (ii) reported the prevalence rates of depression or reported the data for calculating the prevalence and (iii) published in the English language. Reviews, commentaries, case reports and articles performed on animal subjects were excluded. Further, letters to the editor, conference papers, books, editorials and notes were also excluded from the study.

**Methods for data extraction and quality assessment**

Two independent authors (MA and GA) extracted relevant data from the included studies. The data extracted per study included the following information: first author(s) name, sample size, year of publication, the country where the study was conducted, the tools used to assess depression, and the number of positive cases and the corresponding prevalence estimates. We also extracted the number of positive cases and the prevalence rates specifically for male and female participants as well as for the older and younger adolescents.

The Joanna Briggs institute quality assessment tool was employed to evaluate the quality of studies included in the final analysis [26]. The scoring of individual studies was conducted according to the frequency scales that are answered as yes, no, not clear and not applicable. To calculate the total quality score for each study we have utilized the total numbers of positive scores.

**Data synthesis and analysis**

In this study, all statistical analyses were conducted by using the comprehensive meta-analysis software version 3 [27]. The prevalence rates from the individual studies were pooled by using a random-effect meta-analysis [28]. The I² statistics have been used to assess the heterogeneity between studies [28]. The values of I² statistics such as
The prevalence of depression among adolescent with HIV/AIDS (meta-analysis)

The pooled prevalence estimate of depression among adolescents with HIV/AIDS was found to be 26.07% (95% CI 18.92–34.78). There was significant heterogeneity across the studies used for this analysis ($I^2 = 94.75$%; $P < 0.001$) (Fig. 2).

The prevalence of depression was 24.27% for high-quality studies and it was 28.14% for fair-quality studies, although the observed difference was not statistically significant ($P = 0.630$) (Table 3).

In our subgroup analysis based on the tools used to measure the outcome, we found that the prevalence of depression was higher for females (32.15%) than males (25.07%) (Table 3).

Moreover, in our subgroup analysis, we found that the prevalence of depression was higher for older adolescents (15–19 years) (37.09%) than younger adolescents (10–14 years) (29.82%) (Table 3).

Sensitivity analysis

To identify the possible source of heterogeneity across the studies as well as to test the difference across the groups that estimated depression among adolescent, we conducted a stratified analysis by restricting the analysis to the tools used to measure depression (CESD, BDI, CDI and others), the quality of the included studies (high and fair quality), sex (male vs. female) as well as age of the participants (younger and older adolescents). This analysis resulted in the observed variation in the prevalence of depression according to the above four variables (groups) and is not statically significant ($P > 0.05$) (Table 3).

We also conducted a leave-one-out sensitivity analysis to further examine the possible cause of heterogeneity across the studies involved in the analysis. This analysis suggested that the findings of the main analysis are robust and not dependent on a single study. The pooled estimated prevalence of depression varied between 24.11 (95% CI 17.55–20.33) and 28.39 (95% CI 31.38–36.95) after the deletion of a single study (Additional file 1: Fig. S1).
Publication bias
In the current systematic review and meta-analysis, we found no evidence of potential publication bias for the prevalence of depression among adolescents with HIV/AIDS as evidenced by inspection of the funnel plot (symmetric) and results of regression tests associated with the funnel plot (Egger’s test) ($B = -552, SE = 4.98, P = 0.914$) (Fig. 3).

Discussion
Key findings
This study is, to the best of our knowledge, the first systematic review and meta-analysis on the prevalence estimate of depression among adolescents with HIV/AIDS. The review included ten studies that assessed the prevalence of depression among adolescent males and females, which are conducted across seven countries. Our
qualitative and quantitative synthesis indicated that the existing scientific evidence on the prevalence of depression among the adolescent demonstrated a considerable variation depending on the countries where the studies are conducted, the gender of the participants, the tools used, the age of the participants, as well as the reported quality of the studies. The vast majority of the included studies were performed in Africa (70%; \( n = 7 \)) and only three studies were conducted outside Africa such as in the USA (\( n = 1 \)), China (\( n = 1 \)) and Thailand (\( n = 1 \)). Roughly half of the included studies reported prevalence by gender (male vs. female) and age categories (10–14 and 15–19 years) and almost all studies used standard instruments to measure the prevalence of depression among the adolescent.

In general, our final meta-analysis demonstrated that a remarkably higher proportion of adolescents with HIV had depression (26.07%). The estimated prevalence was highest amongst female adolescents (32.15%) than males (25.07%) as well as amongst the older adolescents aged 15–19 years (37.09%) than younger adolescents aged 10–14 years (29.82%). These prevalence rates are notably higher compared to that of the general population, suggesting depression is an important and global public health issue among adolescents with depression requiring urgent attention in terms of prevention and treatments.

### Comparisons with the existing evidence

The prevalence estimates of depression among the adolescent in the current study (26.07%), is 2.48 times higher than the reported prevalence of depression in the general population according to a meta-analytic study conducted on the prevalence of depression in adolescents in the general population (10.5%) [33]. This result indicates that depression which might negatively impact the physical, mental and social lives of individuals, is a burning global issue requiring urgent interventions to alleviate the suffering as well as preventions of further negative consequences [34–37]. There are several explanations for the higher prevalence of depression among the adolescent with HIV when compared with the reported prevalence in the general population: one of the possible reason for this variation could be a significant effect of HIV infection on immunity (reduction in CD4 count) which subsequently increase risk of depression in those adolescents with the problem.

| Study name         | Country   | Sample size | Data collection tool | Prevalence by age groups | Prevalence, cases (n) | Prevalence by sex |
|--------------------|-----------|-------------|----------------------|--------------------------|-----------------------|-------------------|
| Kemigisha [7]      | Uganda    | 336         | CES-D                | 10–14, 37.4%, 222        | 45.8%, 154            | Male 42.5%, 127   |
|                    |           |             |                      | 15–19, 62.3%, 114        |                       | Female 47.8%, 207 |
| Musisi et al. [31] | Uganda    | 85          | ICD-10               | NA                       | 40.8%, 34             | NA                |
|                    |           |             |                      |                          |                       | Male 22.2%, 6/27  |
|                    |           |             |                      |                          |                       | Female 33.3%, 9/27|
| Dow et al. [30]    | Tanzania  | 182         | PHQ-9                | NA                       | 12.1%, 22             | NA                |
|                    |           |             |                      |                          |                       | Male 33.74%, 28/83|
|                    |           |             |                      |                          |                       | Female 30.64%, 19/62|
| Lee [9]            | Thailand  | 54          | CDI                  | 10–14, 23.08%, 9/39      | 27.8%, 15             | Male 22.2%, 6/27  |
|                    |           |             |                      |                          |                       | Female 33.3%, 9/27|
| Kim et al. [4]     | Malawi    | 562         | CDRS-R               | NA                       | 18.9%, 106            | Male 15.4%, 38/247|
|                    |           |             |                      |                          |                       | Female 21.6%, 68/315|
| Lwidiiko et al. [32]| Tanzania | 566         | CDI                  | NA                       | 11.5%, 65             | NA                |
| Zhou et al. [6]    | China     | 145         | CDI                  | 11–14, 23.33%, 7/30      | 32.41%, 47            | Male 33.74%, 28/83|
|                    |           |             |                      |                          |                       | Female 30.64%, 19/62|
| Abebe et al. [3]   | Ethiopia  | 353         | BDI                  | 15–19, 28.04%, 99/353    | 28.04%, 99            | NA                |
| Lewis et al. [10]  | USA       | 166         | BDI                  | NA                       | 34.3%, 57             | NA                |
| Okawa [5]          | Zambia    | 190         | CES-D                | 15–19, 25.3%, 48/190     | 25.3%, 48             | Male 18.75%, 15/90|
|                    |           |             |                      |                          |                       | Female 30%, 33/110|

**BDI** beck depression inventory; **CDI** children’s depression inventory; **CDRS-R** Children’s Depression Rating Scale; **CES-D** Center for Epidemiologic Studies Depression Scale; **PHQ** patient health questionnaire; **ICD** the international classification of disease
Table 2  Qualities of studies included in the systematic review and meta-analysis

| Study name      | Response | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Total |
|-----------------|----------|----|----|----|----|----|----|----|----|----|-------|
| Kemigisha [7]   | Y        | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 9     |
| Musisi et al. [31] | N      | Y  | N  | Y  | Y  | Y  | Y  | Y  | U  |   | 6     |
| Dow et al. [30] | N        | Y  | Y  | N  | Y  | N  | Y  | Y  | U  |   | 6     |
| Lee [9]         | N        | Y  | N  | Y  | Y  | Y  | Y  | Y  | U  |   | 6     |
| Kim et al. [4]  | Y        | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  |   | 9     |
| Lwidiko et al. [32] | Y      | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  |   | 9     |
| Zhuo et al. [6] | Y        | Y  | Y  | N  | Y  | Y  | Y  | Y  | U  |   | 7     |
| Abebe et al. [3] | Y       | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  |   | 9     |
| Lewis et al. [10]| Y        | Y  | N  | Y  | Y  | Y  | Y  | Y  | U  |   | 7     |
| Okawa [5]       | Y        | Y  | N  | Y  | Y  | Y  | Y  | Y  | Y  |   | 8     |

Keys:
Q1–Q9 represents questions used to assess the quality of included studies, which are listed below:
Q1. Was the sample frame appropriate to address the target populations?
Q2. Were the study participants sampled appropriately?
Q3. Was the sample size adequate?
Q4. Were the study subjects and setting described in detail?
Q5. Was the data analysis conducted with sufficient coverage of the identified sample?
Q6. Was a valid method used in the identification of conditions?
Q7. Was the condition measured in a standard, reliable way for all participants?
Q8. Was there an appropriate statistical analysis?
Q9. Was the response rate adequate, and if not, was the low response rate managed appropriately?

Y yes; N no; U unclear; NA not applicable

Fig. 2  The prevalence of depression among adolescent with HIV/AIDS: a random-effect meta-analysis
(those who have reduced CDA count), as suggested in previous studies [22, 38]. The higher prevalence rates of opportunistic infections among adolescents with HIV possibly increase the risks of depression are reported in several prior studies [39]. The other potential reason is that adolescents with HIV are at greater risk to experience stigma, discrimination, social association, or marginalization when compared with the general population which is linked with a greater risk of depression among the exposed individuals [40]. The higher prevalence rates of mental disorders that possibly increasing the risk of depression among adolescents could be the other possible reason for the observed differences [41].

| Subgroups           | Studies, n | Prevalence (%) | 95% CI       | Heterogeneity across the studies | Heterogeneity between groups (P-value) |
|---------------------|------------|----------------|--------------|----------------------------------|---------------------------------------|
| Gender              |            |                |              |                                   |                                       |
| Female              | 5          | 32.15          | 21.53–45.01  | 89.68 < 0.001                    | 0.431                                 |
| Male                | 5          | 25.07          | 14.61–39.56  | 90.09 < 0.001                    |                                       |
| Quality of studies  |            |                |              |                                   |                                       |
| High                | 5          | 24.27          | 14.54–37.65  | 97.07 < 0.001                    | 0.630                                 |
| Fair                | 5          | 28.14          |              | 87.06 < 0.001                    |                                       |
| Tools used          |            |                |              |                                   |                                       |
| BDI                 | 2          | 30.64          | 24.94–37.01  | 52.82 0.145                      | 0.526                                 |
| CDI                 | 3          | 22.13          | 9.91–42.34   | 94.84 < 0.001                    |                                       |
| CES-D               | 2          | 35.04          | 18.00–57.00  | 95.26 < 0.001                    |                                       |
| Others              | 3          | 21.64          | 11.46–37.07  | 92.58 < 0.001                    |                                       |
| Age group           |            |                |              |                                   |                                       |
| 10–14               | 3          | 29.82          | 20.06–42.83  | 56.75 0.099                      | 0.414                                 |
| 15–19               | 5          | 37.09          | 24.72–51.43  | 91.75 < 0.001                    |                                       |

**Table 3** Sensitivity analysis of all studies based on the country of origin, the instrument used, and study quality of the included studies

**Fig. 3** Funnel plot of the risk of publication bias for the prevalence of depression among adolescents with HIV/AIDS
As expected, our study showed that the prevalence of depression was highest in females than males and the older adolescents than younger adolescents, which were in agreement with the reported prevalence rates of depression from adolescents in the general populations, cancer patients, as well as refugees and asylum seekers and [42–44]. The possible reasons for the gender differences in the prevalence of depression include adverse experiences in childhood and adolescence, the sociocultural roles of adverse events (psychological trauma), sexual abuse and the variations in coping skills [45, 46]. The biological and genetic variations could be also among the possible contributing factors for the observed variation [47].

The current systematic review and meta-analysis have found considerable heterogeneity across the studies that determined depression among adolescents with HIV. The observed heterogeneity could be due to the variation in the characteristics of the participants as well as the methodology of the included studies. Regarding the methodological differences, the include studies varied according to the sample size, the tools used to estimate the outcomes, the sampling produces, as well as the source of population. Additionally, the included studies varied according to the gender of the participants, the location where the participants have resided and they are selected from seven countries with certain variations in socioeconomic and cultural backgrounds affecting the mental health of the participants. To identify the possible source of heterogeneity across the studies we conducted stratified analysis by restricting the analysis to the tools used to measure depression (CESD, BDI, CDI and others), the quality of the included studies (high and fair quality), sex (male vs. female) as well as age of the participants (younger and older adolescents) and we observed no significant variation in the prevalence of depression across the groups (P > 0.05).

Strength and limitations
The present study has several strengths. First, being the first systematic review and meta-analysis to determine the prevalence of depression among adolescents with HIV/AIDS. Second, estimating the prevalence rates of depression with regards to the specific gender and age categories. Third, performing a subgroup and sensitivity depending on the origin of the study, the instruments used to estimate depression, as well as the quality of the studies to detect the possible risk of bias.

Several limitations of this systematic review and meta-analysis should be considered. First, the vast majority of the included studies were conducted in developing countries particularly in Africa so that the reported prevalence of depression in the current study may not represent the existing prevalence in the developed countries; second, we have included studies published English language, which suggests that potential studies conducted in other languages might be missed.

The implication of the findings
The current review has many research and clinical implications. First, future studies are needed to investigate the possible reasons for the higher prevalence rates of depression among adolescents with HIV as compared to the reported estimates in the general population. Second, further studies from high and middle-income countries are imperative. Third, early screening and intervention of depression in adolescents with HIV based on coordinated and integrated public health approaches are required to alleviate the suffering and reduce further negative consequences. Fourth, in this meta-analysis virtually all the included studies have used screening instruments to measure depression or reported depressive symptoms rather than diagnosed disorders (requires diagnostic instrument). Thus, future studies into the prevalence of depressive disorders are needed.

Conclusion
This review demonstrated that the prevalence of depression is significantly higher among adolescents with HIV/AIDS, suggesting the benefits of early screening and intervention of depression among those population groups. Further studies investigating the potential reasons for the higher prevalence estimates of depression among adolescents with HIV/AIDS are needed. In addition, studies investigating better mechanisms of screening, prevention and interventions of those problems among adolescents with HIV are needed.

Abbreviations
BDI: Beck depression inventory; CDI: Children’s depression inventory; CDRS-R: Children’s Depression Rating Scale; CES-D: Center for Epidemiologic Studies Depression Scale; PHQ: Patient health questionnaire; ICD: The international classification of disease; NOS: Newcastle–Ottawa scale; PRISMA: Preferred reporting items for systematic reviews and meta-analyses; USA: United States of America.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12981-021-00351-1.

Additional file 1: Figure S1. Snapshot of the details of search terms used in the three databases—PubMed, Scopus and Web of Science.

Acknowledgements
We are delighted to acknowledge all the authors from the included studies.
**References**

1. Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies, are we recommending nicotine replacement therapy in pregnant women and adolescents? Neurotoxicol Teratol. 2008;30(1):1–19.

2. Ayano G, Betts K, Maravilla JC, Alati R. The risk of anxiety disorders in Australia. 3 Department of Psychiatry, Paulo’s Millennium Medical College, Addis Ababa, Ethiopia. 4 Ethiopian Public Health Institute, Addis Ababa, Ethiopia. 2014;17(1):18965.

3. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis.Curr HIV/AIDS Rep. 2014;11(3):291–307.

4. Ayano, Solomon M, Abrahm A. A systematic review and meta-analysis of epidemiology of depression in people living with HIV in east Africa. BMC Psychiatry. 2018;18(1):254.

5. Betancur MN, Lins L, Oliveira IR, Brites C. Quality of life, anxiety and depression among adolescents living with HIV: can social support buffer the impact of stigma? J Affect Disord. 2019;245:82–90.

6. Orban LA, Stein R, Koenig LJ, Conner LC, Rexhouse EL, Rehhouse EL, Lewis JV, LaGrange R. Coping strategies of adolescents living with HIV: disease-specific stresses and responses. AIDS Care. 2010;22(4):420–30.

7. Clayborne ZM, Varin M, Colman I. Systematic review and meta-analysis: adolescent depression and long-term psychosocial outcomes. J Am Acad Child Adolesc Psychiatry. 2019;58(1):72–9.

8. Fergusson DM, Woodward LJ. Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry. 2002;59(3):225–31.

9. Naicker K, Galambos NL, Zeng Y, Senthilselvan A, Colman I. Social, demographic, and health outcomes in the 10 years following adolescent depression. J Adolesc Health. 2013;52(5):533–8.

10. Pearson CR, Micek MA, Pfeiffer J, Matediane E, Jonasse T, Cunguara A, Rao D, Gloyd SS. One year after ART initiation: psychosocial factors associated with stigma among HIV-positive Mozambicans. AIDS Behav. 2009;13(6):1189–96.

11. Lee B, Chhabra M, Oberdorfer P. Depression among vertically HIV-infected adolescents in Northern Thailand. J Int Assoc Physicians AIDS Care. 2011;10(2):89–96.

12. Lewis VJ, Abramowtiz S, Koenig JL, Chandwani S, Orban L. Negative life events and depression in adolescents with HIV: a stress and coping analysis. AIDS Care. 2015;27(10):1265–74.

13. Andrinopoulos K, Clum G, Murphy DA, Harper G, Perez L, Xu J, Cunningham S, Ellen JM. Adolescent medicine trials network for HIVAI: health related quality of life and psychosocial correlates among HIV-infected adolescent and young adult women in the US. AIDS Educ Prev. 2011;23(4):367–81.

14. Larios SE, Davis JN, Gallo LC, Heinrich J, Talavera G. Concerns about stigma, social support and quality of life in low-income HIV-positive Hispanics. Ethn Dis. 2009;19(1):65–70.

15. Buseh AG, Kelber ST, Stevens PE, Park CG. Relationship of symptoms, perceived health, and stigma with quality of life among urban HIV-infected African American men. Public Health Nurs. 2008;25(5):409–19.

16. Greeff M, Uys LR, Wantland D, Makoe L, Chirwa M, Dilamini P, Koihi TW, Mullan J, Naidoo JR, Cuca Y, et al. Perceived HIV stigma and life satisfaction among persons living with HIV infection in five African countries: a longitudinal study. Int J Nurs Stud. 2010;47(4):475–86.

17. Pearson CR, Micek MA, Pfeiffer J, Montoya P, Matediane E, Jonasse T, Cunguara A, Rao D, Gloyd SS. One year after ART initiation: psychosocial factors associated with stigma among HIV-positive Mozambicans. AIDS Behav. 2009;13(6):1189–96.

18. Orban LA, Stein R, Koenig LJ, Conner LC, Rexhouse EL, Rehhouse EL, Lewis JV, LaGrange R. Coping strategies of adolescents living with HIV: disease-specific stresses and responses. AIDS Care. 2010;22(4):420–30.

19. Clayborne ZM, Varin M, Colman I. Systematic review and meta-analysis: adolescent depression and long-term psychosocial outcomes. J Am Acad Child Adolesc Psychiatry. 2019;58(1):72–9.

20. Fergusson DM, Woodward LJ. Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry. 2002;59(3):225–31.

21. Naicker K, Galambos NL, Zeng Y, Senthilselvan A, Colman I. Social, demographic, and health outcomes in the 10 years following adolescent depression. J Adolesc Health. 2013;52(5):533–8.

22. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014;11(3):291–307.

23. Ayano G, Solomon M, Abrahm A. A systematic review and meta-analysis of epidemiology of depression in people living with HIV in east Africa. BMC Psychiatry. 2018;18(1):254.

24. Betancur MN, Lins L, Oliveira IR, Brites C. Quality of life, anxiety and depression in patients with HIV/AIDS who present poor adherence to antiretroviral therapy: a cross-sectional study in Salvador, Brazil. Braz J Infect Dis. 2017;21(5):507–14.

25. Betancur MN, Lins L, Oliveira IR, Brites C. Quality of life, anxiety and depression in patients with HIV/AIDS who present poor adherence to antiretroviral therapy: a cross-sectional study in Salvador, Brazil. Braz J Infect Dis. 2017;21(5):507–14.

26. Devieux JG, Malow RM, Attonito JM, Jean-Gilles M, Rosenberg R, Gaston S, Saint-Jean G, Des champions MM. Post-traumatic stress disorder symptomatology and alcohol use among HIV-seropositive adults in Haiti. AIDS Care. 2013;25(5):1210–8.

27. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 2. Englewood: Biostat; 2005. p. 104.

28. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.

29. Higgins JP, Thompson SS, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
30. Dow DE, Turner EL, Shayo AM, Mmbaga B, Cunningham CK, O'Donnell K. Evaluating mental health difficulties and associated outcomes among HIV-positive adolescents in Tanzania. AIDS Care. 2016;28(7):825–33.
31. Musisi S, Kiyingi E. Emotional and behavioural disorders in HIV seropositive adolescents in urban Uganda. East Afr Med J. 2009;86(1):16–24.
32. Lwidyko A, Kibusi SM, Nyundo A, Mpondoo BCT. Association between HIV status and depressive symptoms among children and adolescents in the southern highlands zone, Tanzania: a case–control study. Plos One. 2018;13(2):e0193145.
33. Balázs J, Mikkó M, Keresztrény A, Hoven CW, Carli V, Wasserman C, Agter A, Bobes J, Brunner R, Cosman D, et al. Adolescent subthreshold-depression and anxiety: psychopathology, functional impairment and increased suicide risk. J Child Psychol Psychiatry. 2013;54(6):670–7.
34. Ohmberger J, Fichera E, Sutton M. The relationship between physical and mental health: a mediation analysis. Soc Sci Med. 2017;195:42–9.
35. Freedland KE, Carney RM. Depression as a risk factor for adverse outcomes in coronary heart disease. BMC Med. 2013;11(1):131.
36. Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7(6):323–31.
37. Knight MJ, Baune BT. Psychosocial dysfunction in major depressive disorder-rationale, design, and characteristics of the cognitive and emotional recovery training program for depression (CERT-D). Front Psychiatry. 2017;8:280.
38. Kaharuza FM, Bunnell R, Moss S, Purcell DW, Bikaako-Kajura W, Wamai N, Downing R, Solberg P, Coutinho A, Mermin J. Depression and CD4 cell count among persons with HIV infection in Uganda. AIDS Behav. 2006;10(4 Suppl):S105–11.
39. Tesfaw G, Ayano G, Awoke T, Assefa D, Birhanu Z, Mihretie G, Abebe G. Prevalence and correlates of depression and anxiety among patients with HIV on-follow up at Alert Hospital, Addis Ababa, Ethiopia. BMC Psychiatry. 2016;16(1):368.
40. Kimera E, Vindevogel S, Reynaert D, Justice KM, Rubalhayo J, De Maeyer J, Engelen A-M, Musanje K, Bilsen J. Experiences and effects of HIV-related stigma among youth living with HIV/AIDS in Western Uganda: a photo-voice study. PLoS ONE. 2020;15(4):e023259.
41. Vreeman RC, McCoy BM, Lee S. Mental health challenges among adolescents living with HIV. J Int AIDS Soc. 2017;20(Suppl 3):21497.
42. Khiesz-Masjedi MF, Shokrgozar S, Abdollahi E, Golshahi M, Sharif-Ghaziani Z. Comparing depressive symptoms in teenage boys and girls. J Family Med Prim Care. 2017;6(4):775–9.
43. Piccinelli M, Wilkinson G. Gender differences in depression: critical review. Br J Psychiatry. 2000;177(6):486–92.
44. Blackmore R, Gray KM, Boyle JA, Fazel M, Ranasinha S, Fitzgerald G, Misso M, Gibson-Helm M. Systematic review and meta-analysis: the prevalence of mental illness in child and adolescent refugees and asylum seekers. J Am Acad Child Adolesc Psychiatry. 2020;59(6):705–14.
45. Savant NS, Vanjari NA, Khopkar U. Gender differences in depression, coping, stigma, and quality of life in patients of vitiligo. Dermatol Res Pract. 2019;2019:6879412.
46. Felsten G. Gender and coping: use of distinct strategies and associations with stress and depression. Anxiety Stress Coping. 1998;11(4):289–309.
47. Albert PR. Why is depression more prevalent in women? J Psychiatry Neurosci. 2015;40(4):219–21.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.